Larvol Delta - Alpha-Cognition-Announces-a-44-Million-Exclusive-Licensing-Agreement-for-the-Development-and-Commercialization-of-ZUNVEYL-benzgalantamine-an-FDAApproved-Treatment-for-MildtoModerate-Alzheimers-Disease-in-China

Zunveyl (benzgalantamine) - Alpha Cognition

https://www.businesswire.com/news/home/20250108752271/en/Alpha-Cognition-Announces-a-44-Million-Exclusive-Licensing-Agreement-for-the-Development-and-Commercialization-of-ZUNVEYL-benzgalantamine-an-FDA-Approved-Treatment-for-Mild-to-Moderate-Alzheimer%E2%80%99s-Disease-in-China

Jan 8, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next